Teva infringed UCB patent, rules Fed Circuit

25-06-2019

Teva infringed UCB patent, rules Fed Circuit

JHVEPhoto / Shutterstock.com

The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro (rotigotine), a patch to treat Parkinson’s disease.


US Court of Appeals for the Federal Circuit, Teva, UCB, Parkinson’s disease, Neupro, Actavis, Watson Laboratories, patent infringement

More on this story

UCB to acquire Ra Pharmaceuticals in $2bn deal
14-10-2019

LSIPR